Rocketing to a price of $18.98 during today's afternoon trading session, shares of Summit Therapeutics are still -40.47% below their average target price of $31.87. Could there be more upside potential for the stock? Analysts are giving SMMT an average rating of buy and target prices ranging from $11.78221 to $41.194283 dollars per share.
The market, on the other hand, is a bit more pessimistic. Summit Therapeutics's short interest -- meaning the percentage of its share float that is being shorted on an expectation of a price decline -- is quite high at 27.3%. The float includes only shares that are available for public trading, and excludes preferred shares.
When a stock is sold short, it means an investor has borrowed shares of the stock from their broker, and then sold them at the going market price. The investor hopes for the price to decline, so that they might buy those shares back at a lower price in the future. Once they do, they can return the borrowed shares to their broker, and keep the profit they made on the transaction.
A possible indicator of market sentiment on a stock (besides its share price, of course) is the portion of institutional investors that make up its shareholders. Institutions such as banks, hedge funds, and wealth managers deploy significant resources towards identifying good investments. If they are invested heavily in a given company's stock, it could mean it's a good investment. Or it could mean the company is being targeted by a takeover attempt.
For what it's worth, institutions own 13.9% of Summit Therapeutics's shares, which is an average amount. It means that many institutions are invested, but not to the extent that they would be in a stock such as Apple or Amazon, whose institutional ownership rates hover around 60%. Bear in mind that institutional ownership is just one piece of the puzzle in determining market sentiment, and you should not consider this factor alone in making an investment decision.
Overall, there is mixed market sentiment on Summit Therapeutics because its an analyst consensus of strong upside potential, a buy rating, an unusually large proportion of its shares sold short, and a very small number of institutional investors. Warren Buffett famously said that in the short term, markets are voting mechanisms, but in the long term, they are weighing mechanisms. This means that long term investors should be aware of a stock's fundamentals before committing.
Buffett was one of the fist investors to focus on free cash flow as a yardstick for a company's health. Here are SMMT's recent cash flows:
| Date Reported | Cash Flow from Operations ($ k) | Capital expenditures ($ k) | Free Cash Flow ($ k) | YoY Growth (%) |
|---|---|---|---|---|
| 2024 | -142,106 | 139 | -142,245 | -85.0 |
| 2023 | -76,760 | 128 | -76,888 | -82.17 |
| 2022 | -41,582 | 624 | -42,206 | 42.1 |
| 2021 | -72,587 | 306 | -72,893 | -50.2 |
| 2020 | -48,111 | 421 | -48,532 | -37.63 |
| 2019 | -35,106 | 157 | -35,263 |
